MuzevichKMLeeKB. Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia: case report and review of the literature. Ann Pharmacother. 2013;47:e25.
2.
BoullataJI. Drug disposition in obesity and protein-energy malnutrition. Proc Nutr Soc. 2010;69:543-550.
3.
JanmahasatianSDuffullSBAshSWardLCByrneNMGreenB. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44:1051-1065.
4.
MersfelderTLSmithCL. Linezolid pharmacokinetics in an obese patient. Am J Health Syst Pharm. 2005;62:464, 467.
5.
TsujiYHirakiYMatsumotoK. Evaluation of the pharmacokinetics of linezolid in an obese Japanese patient. Scand J Infect Dis. 2012;44:626-629.
6.
BoullataJI. Drug administration through an enteral feeding tube. Am J Nurs. 2009;109(10):34-42.
7.
BeringerPNguyenMHoemN. Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob Agents Chemother. 2005;49:3676-3681.
